UNSPSC 51434937: Hydralazine/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434937 Hydralazine/reserpine is a Commodity code that maps narrowly to a single pharmaceutical product line, but state and local governments rarely solicit this specific drug in isolation. Recent opportunities tagged to this code actually represent broader pharmaceutical procurement — emergency medical services medications, multi-source generic drugs, and pharmacy benefit program management — where hydralazine or reserpine may appear as line items within larger medication bundles rather than as standalone purchases. The issuing bodies are diverse: municipal fire and rescue departments (Tampa Fire Rescue through the City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance with Oregon participation). Work being solicited ranges from small sealed-bid supplies of Advanced Life Support medications for emergency response to large multi-state RFPs for generic pharmaceuticals and OTC products distributed through authorized drug wholesalers, and exploratory RFIs into direct-to-manufacturer pharmacy benefit models that would bypass traditional wholesaler channels.

Geographic activity centers on Texas and Minnesota — the Texas HHS RFI and the MMCAP RFP (administered by Minnesota with Oregon participation) represent the most recent substantive opportunities. The City of Tampa's sealed bid for Advanced Life Support Medications (Bid 26P00188, due April 8, 2026, estimated contract value $40,000) solicits four specific medication line items including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with award within 120 days and a one-year term plus optional renewals; the solicitation includes a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802, due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, with pricing weighted at 75 percent and compliance at 25 percent, requiring vendors to work through three authorized wholesalers and maintain $5 million commercial general liability insurance. The Texas HHS RFI (HHS0017013, posted March 27, 2026) is exploratory, seeking vendor capabilities for direct manufacturer-to-state contracting models outside traditional PBM and wholesaler relationships, with no award value or formal timeline specified.